Literature DB >> 9583688

Abrogation of c-Raf expression induces apoptosis in tumor cells.

Q C Lau1, S Brüsselbach, R Müller.   

Abstract

Signal transduction pathways involving the c-Raf protein kinase are frequently activated in tumor cells. We have addressed the relevance of this activation by a loss-of-function approach. An anti-sense phosphorothioate oligonucleotide (ODN) specifically targeted against c-raf mRNA (Monia et al., 1996a) was used to block c-Raf protein expression in four different cell lines derived from lung, cervical, prostate and colon carcinomas. Concomitant with the abrogation of c-Raf expression we observed the occurrence of classical apoptotic markers, including chromatin condensation, inter-nucleosomal DNA cleavage, annexin V binding and cleavage of PARP, which was followed by cell death, affecting most of the cell population. This induction of apoptosis occurred independent of the p53 status of the cell. These findings demonstrate that c-Raf can protect tumor cells from undergoing programmed cell death, and suggest that the interference with c-Raf expression or function by ODNs or specific drugs could represent a powerful means for improving the efficacy of anti-cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9583688     DOI: 10.1038/sj.onc.1201709

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Gene silencing by synthetic U1 adaptors.

Authors:  Rafal Goraczniak; Mark A Behlke; Samuel I Gunderson
Journal:  Nat Biotechnol       Date:  2009-02-15       Impact factor: 54.908

3.  Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene.

Authors:  M Mikula; M Schreiber; Z Husak; L Kucerova; J Rüth; R Wieser; K Zatloukal; H Beug; E F Wagner; M Baccarini
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

4.  MEK kinase activity is not necessary for Raf-1 function.

Authors:  M Hüser; J Luckett; A Chiloeches; K Mercer; M Iwobi; S Giblett; X M Sun; J Brown; R Marais; C Pritchard
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

5.  Protective role of Raf-1 in Salmonella-induced macrophage apoptosis.

Authors:  V Jesenberger; K J Procyk; J Rüth; M Schreiber; H C Theussl; E F Wagner; M Baccarini
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

6.  Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer.

Authors:  F McPhillips; P Mullen; B P Monia; A A Ritchie; F A Dorr; J F Smyth; S P Langdon
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

Review 7.  [Current status of Akt in non-small cell lung cancer].

Authors:  Bojiang Chen; Weimin Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-11

Review 8.  Antisense oligonucleotide therapy for urologic tumors.

Authors:  Ingo Kausch; Andreas Böhle
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 2.862

9.  C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.

Authors:  Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Patricia J Conrad; John C Schmitz; Mario Sznol; Robert L Camp; David L Rimm; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-09-08       Impact factor: 13.801

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.